{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:37:57Z","timestamp":1787168277238,"version":"build-2736575974"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.cyto.2023.156140","type":"journal-article","created":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T19:39:07Z","timestamp":1675366747000},"page":"156140","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Recovery of host adaptive immune function promoted the reduction of hepatitis B surface antigen in nucleoside analog-experienced chronic hepatitis B patients with low hepatitis B surface antigen levels"],"prefix":"10.1016","volume":"164","author":[{"given":"Qian","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xicheng","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huimin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinjie","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9959","key":"10.1016\/j.cyto.2023.156140_b0005","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1016\/S0140-6736(14)60220-8","article-title":"Hepatitis B virus infection","volume":"384","author":"Tr\u00e9po","year":"2014","journal-title":"Lancet."},{"key":"#cr-split#-10.1016\/j.cyto.2023.156140_b0010.1","doi-asserted-by":"crossref","unstructured":"EASL 2017, Clinical Practice Guidelines on the management of hepatitis B virus infection, J. Hepatol. 67","DOI":"10.1016\/j.jhep.2017.03.021"},{"key":"#cr-split#-10.1016\/j.cyto.2023.156140_b0010.2","doi-asserted-by":"crossref","unstructured":"(2) (2017) 370-398. doi:10.1016\/j.jhep.2017.03.021.","DOI":"10.1016\/j.jhep.2017.03.021"},{"issue":"4","key":"10.1016\/j.cyto.2023.156140_b0015","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/j.1478-3231.2009.02192.x","article-title":"Validation of FIB-4 and comparison with other simple noninvasive indices for predicting liver fibrosis and cirrhosis in hepatitis B virus-infected patients","volume":"30","author":"Kim","year":"2010","journal-title":"Liver Int."},{"issue":"6","key":"10.1016\/j.cyto.2023.156140_b0020","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1200\/JCO.2014.57.9151","article-title":"Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade","volume":"33","author":"Johnson","year":"2015","journal-title":"J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.cyto.2023.156140_b0025","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/cld.728","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"12","author":"Terrault","year":"2018","journal-title":"Clin. Liver Dis. (Hoboken)."},{"issue":"10","key":"10.1016\/j.cyto.2023.156140_b0030","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1111\/apt.14629","article-title":"Systematic review with meta-analysis: combination treatment of regimens based on pegylated interferon for chronic hepatitis B focusing on hepatitis B surface antigen clearance","volume":"47","author":"Qiu","year":"2018","journal-title":"Alim. Pharmacol. Ther."},{"issue":"12","key":"10.1016\/j.cyto.2023.156140_b0035","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1016\/j.cgh.2020.04.037","article-title":"Incidence and factors associated with HBV relapse after cessation of entecavir or tenofovir in patients with HBsAg below 100 IU\/mL","volume":"18","author":"Tseng","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"11","key":"10.1016\/j.cyto.2023.156140_b0040","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1016\/j.cgh.2015.06.002","article-title":"Association between level of hepatitis b surface antigen and relapse after entecavir therapy for chronic hepatitis B virus infection","volume":"13","author":"Chen","year":"2015","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.cyto.2023.156140_b0045","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s12072-019-09998-5","article-title":"Use of HBsAg quantification in the natural history and treatment of chronic hepatitis B","volume":"14","author":"Mak","year":"2020","journal-title":"Hepatol. Int."},{"key":"10.1016\/j.cyto.2023.156140_b0050","doi-asserted-by":"crossref","unstructured":"P. Hu, J. Shang, W. Zhang, G. Gong, Y. Li, X. Chen, J. Jiang, Q. Xie, X. Dou, Y. Sun, Y. Li, Y. Liu, G. Liu, D. Mao, X. Chi, H. Tang, X. Li, Y. Xie, X. Chen, J. Jiang, P. Zhao, J. Hou, Z. Gao, H. Fan, J. Ding, D. Zhang, H. Ren, HBsAg Loss with Peg-interferon Alfa-2a in Hepatitis B patients with partial response to nucleos(t)ide analog: new switch study, J. Clin. Transl. Hepatol. 6(1) (2018) 25\u201334. doi:10.14218\/JCTH.2017.00072.","DOI":"10.14218\/JCTH.2017.00072"},{"issue":"46","key":"10.1016\/j.cyto.2023.156140_b0055","doi-asserted-by":"crossref","first-page":"10210","DOI":"10.3748\/wjg.v22.i46.10210","article-title":"Effect of switching from treatment with nucleos(t)ide analogs to pegylated interferon \u03b1-2a on virological and serological responses in chronic hepatitis B patients","volume":"22","author":"He","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.cyto.2023.156140_b0060","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.intimp.2018.06.043","article-title":"Recovery of circulating CD56 NK cells and the balance of Th17\/Treg after nucleoside analog therapy in patients with chronic hepatitis B and low levels of HBsAg","volume":"62","author":"Liu","year":"2018","journal-title":"Int. Immunopharmacol."},{"issue":"1","key":"10.1016\/j.cyto.2023.156140_b0065","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/cei.13486","article-title":"Combination of pegylated interferon-alpha and nucleos(t)ide analogue treatment enhances the activity of natural killer cells in nucleos(t)ide analogue experienced chronic hepatitis B patients","volume":"202","author":"Pang","year":"2020","journal-title":"Clin. Exp. Immunol."},{"issue":"1","key":"10.1016\/j.cyto.2023.156140_b0070","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000018462","article-title":"The serum interleukin-26 level is a potential biomarker for chronical hepatitis B","volume":"99","author":"Luo","year":"2020","journal-title":"Medicine"},{"issue":"2","key":"10.1016\/j.cyto.2023.156140_b0075","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/hep.23327","article-title":"Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B","volume":"51","author":"Chang","year":"2010","journal-title":"Hepatology."},{"issue":"9865","key":"10.1016\/j.cyto.2023.156140_b0080","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S0140-6736(12)61425-1","article-title":"Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study","volume":"381","author":"Marcellin","year":"2013","journal-title":"Lancet."},{"issue":"2","key":"10.1016\/j.cyto.2023.156140_b0085","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/apt.12344","article-title":"Meta-analysis: the impact of oral anti-viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis B","volume":"38","author":"Singal","year":"2013","journal-title":"Aliment Pharmacol. Ther."},{"issue":"15","key":"10.1016\/j.cyto.2023.156140_b0090","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1056\/NEJMoa033364","article-title":"Lamivudine for patients with chronic hepatitis B and advanced liver disease","volume":"351","author":"Liaw","year":"2004","journal-title":"New England J. Med."},{"issue":"6","key":"10.1016\/j.cyto.2023.156140_b0095","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1002\/hep.27723","article-title":"Long-term effect of antiviral therapy on disease course after decompensation in patients with hepatitis B virus-related cirrhosis","volume":"61","author":"Jang","year":"2015","journal-title":"Hepatology."},{"issue":"1","key":"10.1016\/j.cyto.2023.156140_b0100","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jama.295.1.65","article-title":"Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level","volume":"295","author":"Chen","year":"2006","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.cyto.2023.156140_b0105","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s12016-014-8465-4","article-title":"Cytokine-Mediated Immunopathogenesis of Hepatitis B Virus Infections","volume":"50","author":"Li","year":"2016","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"10.1016\/j.cyto.2023.156140_b0110","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.molimm.2018.10.011","article-title":"Circulating PD-1CXCR5CD4 T cells are associated with a decrease in hepatitis B surface antigen levels in patients with chronic hepatitis B who are receiving peginterferon-\u03b1 therapy","volume":"103","author":"Zhang","year":"2018","journal-title":"Mol. Immunol."},{"issue":"1","key":"10.1016\/j.cyto.2023.156140_b0115","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/j.1600-065X.2009.00782.x","article-title":"Molecular mechanism and function of CD40\/CD40L engagement in the immune system","volume":"229","author":"Elgueta","year":"2009","journal-title":"Immunol. Rev."},{"issue":"2","key":"10.1016\/j.cyto.2023.156140_b0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.imbio.2019.151899","article-title":"Mechanistic basis of co-stimulatory CD40-CD40L ligation mediated regulation of immune responses in cancer and autoimmune disorders","volume":"225","author":"Chand Dakal","year":"2020","journal-title":"Immunobiology"},{"key":"10.1016\/j.cyto.2023.156140_b0125","doi-asserted-by":"crossref","first-page":"8941260","DOI":"10.1155\/2016\/8941260","article-title":"Effector, memory, and dysfunctional CD8(+) T cell fates in the antitumor immune response","volume":"2016","author":"Reiser","year":"2016","journal-title":"J. Immunol. Res."},{"issue":"2","key":"10.1016\/j.cyto.2023.156140_b0130","first-page":"174","article-title":"Effect of entecavir on CD4+ T-cell subpopulations in patients with chronic hepatitis B","volume":"15","author":"Tian","year":"2016","journal-title":"Ann. Hepatol."},{"issue":"5","key":"10.1016\/j.cyto.2023.156140_b0135","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.3892\/mmr.2014.2042","article-title":"Telbivudine decreases proportion of peripheral blood CD4+CD25+CD127low T cells in parallel with inhibiting hepatitis B virus DNA","volume":"9","author":"Yan","year":"2014","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.cyto.2023.156140_b0140","doi-asserted-by":"crossref","unstructured":"X. Yang, J. Li, J. Liu, M. Gao, L. Zhou, W. Lu, Relationship of Treg\/Th17 balance with HBeAg change in HBeAg-positive chronic hepatitis B patients receiving telbivudine antiviral treatment: a longitudinal observational study, Medicine 96 (23) (2017) e7064, doi: 10.1097\/MD.0000000000007064.","DOI":"10.1097\/MD.0000000000007064"}],"container-title":["Cytokine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466623000182?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466623000182?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T21:47:27Z","timestamp":1760910447000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043466623000182"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":29,"alternative-id":["S1043466623000182"],"URL":"https:\/\/doi.org\/10.1016\/j.cyto.2023.156140","relation":{},"ISSN":["1043-4666"],"issn-type":[{"value":"1043-4666","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recovery of host adaptive immune function promoted the reduction of hepatitis B surface antigen in nucleoside analog-experienced chronic hepatitis B patients with low hepatitis B surface antigen levels","name":"articletitle","label":"Article Title"},{"value":"Cytokine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cyto.2023.156140","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"156140"}}